IOCN and UKSACT Board joint letter to NHSE
Hello All
One of the pressing issues the BOPA Immunotherapy Specialist Advisory Group has been working over the past year, is addressing/improving the access to second line immunosuppressants for the management of immune-related toxicities.
You may be aware we have produced monographs to support the use in clinical practice but also identify that there is real disparity in terms of access to theses medications nationally.
With this in mind, BOPA have worked with the other members of the UK SACT board as well as the IOCN to formally write to NHSE to ask them to address this issue.
We attach a copy of this letter for the membership to read, and will update you with the outcome in due course.
Kr
Alice and Meera – Co-Chairs of the Immunotherapy Group
